Vienna - Delayed Quote EUR

Incyte Corporation (INCY.VI)

70.36

0.00

(0.00%)

At close: July 23 at 10:00:00 PM GMT+2

Incyte Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Incyte ( NASDAQ:INCY ) Full Year 2024 Results Key Financial Results Revenue: US$4.24b (up 15% from FY 2023). Net...

Simply Wall St. 2 days ago

INCY
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones

WILMINGTON, Del., February 10, 2025--Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones

Business Wire 3 days ago

INCY
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WILMINGTON, Del., February 07, 2025--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire 5 days ago

INCY
Exploring High Growth Tech Stocks In January 2025

In the last week, the United States market has been flat, but it has seen a significant rise of 25% over the past year with earnings forecast to grow by 15% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and robust financial health to capitalize on these favorable conditions.

Simply Wall St. 14 days ago

GDS

INCY

ASND
Incyte to Report Fourth Quarter and Year-End 2024 Financial Results

WILMINGTON, Del., January 21, 2025--Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2024 financial results conference call and webcast for 8:00 a.m. ET on Monday, February 10, 2025.

Business Wire 23 days ago

INCY
Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes

Incyte (Nasdaq:INCY) and Syndax Pharmaceuticals (Nasdaq:SNDX) today announced that the U.S. Food and Drug Administration (FDA) has approved Niktimvo™ (axatilimab-csfr) in 9 mg and 22 mg vial sizes. The Companies expect product to be available for order in the U.S. in early February. Niktimvo is approved for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg (88.2 lbs). Nik

PR Newswire 28 days ago

INCY

SNDX
Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

WILMINGTON, Del., January 13, 2025--Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

Business Wire last month

INCY
Exploring Three High Growth Tech Stocks in the United States

The United States market has shown robust performance, climbing by 2.8% over the past week and rising 25% over the past year, with earnings forecasted to grow annually by 15%. In this thriving environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these favorable conditions.

Simply Wall St. last month

SMCI

NOW

INCY
Incyte price target raised to $70 from $68 at Wells Fargo

Wells Fargo raised the firm’s price target on Incyte (INCY) to $70 from $68 and keeps an Equal Weight rating on the shares. The firm adjusted price targets in the Smid-cap biotechnology group as part of its 2025 outlook. Wells top sector picks target Ascendis Pharma (ASND), aTyr Pharma (ATYR), Rhythm Pharmaceuticals (RYTM), and Xencor (XNCR). Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRa

TipRanks last month

INCY
Incyte to Present at Upcoming Investor Conference

WILMINGTON, Del., December 17, 2024--Incyte (Nasdaq: INCY) announced today that it will present at the 43rd Annual J. P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 am (PST).

Business Wire last month

INCY
$Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma$

Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma

WILMINGTON, Del., December 10, 2024--Late-Breaking Tafasitamab (Monjuvi®) Data Demonstrate Significantly Improved Progression-Free Survival in Relapsed or Refractory Follicular Lymphoma

Business Wire 2 months ago

INCY
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer

WILMINGTON, Del., December 07, 2024--Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz) in Combination with Platinum-Based Chemotherapy in NSCLC

Business Wire 2 months ago

INCY
Exploring 3 High Growth Tech Stocks in the United States

Over the last 7 days, the United States market has risen by 1.6%, and in the past year, it has climbed an impressive 32%, with earnings forecasted to grow by 15% annually. In light of these robust market conditions, identifying high growth tech stocks requires a focus on companies that demonstrate strong innovation potential and scalability to align with this upward trajectory.

Simply Wall St. 2 months ago

SMCI

INCY

IREN
Incyte Announces Updated Presentation Time for Upcoming Investor Conference

WILMINGTON, Del., November 26, 2024--Incyte (Nasdaq:INCY) announced today that it will now present at Citi’s 2024 Global Healthcare Conference on Tuesday, December 3, 2024 at 8:00 a.m.

Business Wire 2 months ago

INCY
Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting

WILMINGTON, Del., November 25, 2024--Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting

Business Wire 2 months ago

INCY
Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered.

Incyte stock tumbled Tuesday after the company scrapped one drug and paused enrollment in the study of another.

Investor's Business Daily 2 months ago

INCY
Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs

WILMINGTON, Del., November 18, 2024--Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs

Business Wire 2 months ago

INCY
Bank of America Turns Bullish on These 2 Lesser-Known Stocks

President John Kennedy famously said that a rising tide lifts all boats, and that is looking to be the case in today’s bullish stock market environment. The big question for investors now is, where to buy in, to ride that rising tide? The stock analysts at Bank of America may have some suggestions. They’ve been scouring the market – looking for lesser-known names that offer solid potential for gains. On two of these stocks, the analysts have upgraded their stance – a clear sign for investors tha

TipRanks 3 months ago

BEKE

INCY
Incyte to Present at Upcoming Investor Conferences

WILMINGTON, Del., October 30, 2024--Incyte (Nasdaq: INCY) announced today that it will present at the following investor conferences during the month of November:

Business Wire 3 months ago

INCY
Incyte Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Incyte ( NASDAQ:INCY ) Third Quarter 2024 Results Key Financial Results Revenue: US$1.14b (up 24% from 3Q 2023). Net...

Simply Wall St. 3 months ago

INCY

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Incyte Corporation (INCY.VI)

Incyte Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Exploring High Growth Tech Stocks In January 2025

Incyte to Report Fourth Quarter and Year-End 2024 Financial Results

Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes

Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

Exploring Three High Growth Tech Stocks in the United States

Incyte price target raised to $70 from $68 at Wells Fargo

Incyte to Present at Upcoming Investor Conference

Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma

Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer

Exploring 3 High Growth Tech Stocks in the United States

Incyte Announces Updated Presentation Time for Upcoming Investor Conference

Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting

Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered.

Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs

Bank of America Turns Bullish on These 2 Lesser-Known Stocks

Incyte to Present at Upcoming Investor Conferences

Incyte Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags